On November 14, 2019 AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, reported that it will present at Jefferies 2019 London Healthcare Conference in London, UK, taking place November 20 – 21, 2019 (Press release, AC Immune, NOV 14, 2019, View Source [SID1234551309]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA, will discuss the Company’s world-leading pipeline and Roadmap to Successful Therapies for Neurodegenerative Diseases, with a focus on its clinical programs targeting misfolded Tau protein. AC Immune is addressing the full spectrum of Tau pathology by detecting and inhibiting both early seeding and extracellular spreading of Tau with its internally discovered, best-in-class small molecule (Partner: Eli Lilly), antibody (Partner: Roche/Genentech) and vaccine (Partner: Janssen) therapies, as well as its highly specific Tau diagnostic agents (Partner: Life Molecular Imaging).

Jefferies 2018 London Healthcare Conference
Date: November 21, 2019 | 5:20 pm GMT
Format: Fireside chat
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune

A webcast of the presentation will be available on the Events Page of AC Immune’s website and at the Jefferies 2018 Healthcare Conference website and will be active for 90 days following the event.